Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Great publication about improving the efficacy of adoptive T-Cell therapy in solid tumours by using 3rd generation CAR-T cells.
Great publication about improving the efficacy of adoptive T-Cell therapy in solid tumours by using 3rd generation CAR-T cells.
Scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
In Vitro Technologies would like to congratulate Dr. Andreas Behren and the Cancer Immunobiology team at the Olivia Newton-John Cancer Research (ONJCRI) Institute in Melbourne for winning the Advanced Cell Diagnostics $40,000 USD research grant.
In Vitro Technologies are proud to work closely with the new NSW Health Statewide Biobank, the largest biobank in the southern hemisphere.
In the latest vote of confidence that cellular immunotherapy is going to live up to its potential for transforming the way cancer is treated, this week Gilead Sciences purchased Kite Pharma, a leader in the development of chimeric antigen receptor (CAR) T cells, for $11.9 billion dollars.
Proteome Profilerâ„¢ Antibody Arrays allow for the measurement of up to 119 proteins in a single sample.
MANASSAS, VA (August 8, 2017) — ATCC, a global leader in biological materials development, management, and standards, in partnership with the Institute for Life Science Entrepreneurship (ILSE) and the ATCC...
Join us at the Protein Expression Workshop meeting for a hands-on demonstration of the new Minifors 2 from Infors-HT and the new eve bioprocess control software.Â
Enter below to win a FREE Allentown Service and NATA Certification.
Findings from the new study—published recently in the Journal of Medicinal Chemistry in an article entitled “Development of a Potent Wound Healing Agent Based on the Liver Fluke Granulin Structural...